Dr. Ulrich Julius

This article presents the generally accepted indications for LDL apheresis treatment. The available LDL apheresis methods differ with respect to acute relative reductions of LDL cholesterol; mean values after the LDL apheresis treatments are not different. Serum triglycerides, HDL-cholesterol, and lipoprotein(a) are also acutely reduced. Available LDL apheresis methods differ with respect to their impact on the coagulation system, on C-reactive protein and on leukocyte count. Cardiovascular events are clearly reduced by the LDL apheresis methods. There is an urgent need to prospectively compare the different LDL apheresis methods taking into account hard end points. The lower target values for LDL cholesterol suggested by international guidelines for high-risk patients will certainly require a more widespread use of LDL apheresis.

1 May 2015 in Atherosclerosis Supplements

Journal Article

Effects of different lipoprotein apheresis methods on serum protein levels

Ulrich Julius

G. Siegert

H. Kostka

U. Schatz

B. Hohenstein

20 September 2021 in Biomedicines

Journal Article

Modern Approaches to Lower Lipoprotein(a) Concentrations and Consequences for Cardiovascular Diseases

Viktoria A. Aleekseevna Korneva

Tatiana Kuznetsova

Ulrich Julius

Lipoprotein(a) (Lp(a)) is a low density lipoprotein particle that is associated with poor cardiovascular prognosis due to pro-atherogenic, pro-thrombotic, pro-inflammatory and pro-oxidative properties. Traditional lipid-lowering therapy does not provide a sufficient Lp(a) reduction. For PCSK9 inhibitors a small reduction of Lp(a) levels could be shown, which was associated with a reduction in cardiovascular events, independently of the effect on LDL cholesterol. Another option is inclisiran, for which no outcome data are available yet. Lipoprotein apheresis acutely and in the long run decreases Lp(a) levels and effectively improves cardiovascular prognosis in high-risk patients who cannot be satisfactorily treated with drugs. New drugs inhibiting the synthesis of apolipoprotein(a) (an antisense oligonucleotide (Pelacarsen) and two siRNA drugs) are studied. Unlike LDL-cholesterol, for Lp(a) no target value has been defined up to now. This overview presents data of modern capabilities of cardiovascular risk reduction by lowering Lp(a) level.

1 November 2017 in Atherosclerosis Supplements

Journal Article

History of lipidology and lipoprotein apheresis

Ulrich Julius

About Me

Arthur Ulrich Julius I graduated from the Medizinische Akademie Dresden as Doctor of Medicine in 1969. In 1974 I was recognized as a specialist in internal medicine, in 1977 as a subspecialist in diabetology and metabolic diseases, and in 1993 as an endocrinologist. Since 1969 I have worked at the Medizinische Akademie Dresden in the department of Internal Medicine and cared for patients with metabolic disorders (diabetes, lipid disorders). In 1990 I founded the Dresden Center for Extracorporeal Therapy, where nowadays there are 159 patients being treated with lipoprotein apheresis. In 1994 I was appointed as C3-Professor for Internal Medicine/Metabolic diseases, after the Medizinische Akademie was changed into the Medical Faculty of the Technische Universität Dresden. My research interests were focused on Metabolic Syndrome, lipid disorders, and in the last few years mainly on several aspects of lipoprotein apheresis. I am a member of the EASD and the ISFA. Authorship: substantial contributions to the conception of the work; analysis and interpretation of data for the work; final approval of the version to be published; agreement to be accountable for all aspects of the work.

Dr. Ulrich Julius

Dr. Ulrich Julius

Research Focus & Metrics

Academic Career Length

Publication Type Breakdown

Representative Publications

About Me